Camlin Fine Sciences
- Market cap
- ₹ 1,544 Cr.
- P/E
- 66.7x
- P/B
- 1.55x
- 52-week range
- 78.8 – 202.45
- ROE
- 4%
- ROCE
- 5%
- Dividend yield
- 0%
- Debt / equity
- 0.69
- Sector
- Chemicals & Petrochemicals
- Industry
- Specialty Chemicals
- Listed on
- NSE, BSE
About
Camlin Fine Sciences Limited is an India-based specialty chemicals company, which is engaged in the research, development, manufacturing and marketing of specialty chemicals, ingredients, and additive blends. The Company's products portfolio is categorized into shelf-life solutions, performance chemicals, aroma ingredients, and health and wellness. Its products include catechol, tert-butylhydroquinone (TBHQ), Butylated Hydroxyanisole (BHA), Butylated Hydroxytoluene (BHT), Ascorbyl Palmitate (ASP), 4-Tertiary Butyl Catechol, Xtendra, Guaiacol, Para DiMethoxy Benzene, NaSure, Hydroquinone, and Veratrole. Its aroma ingredients mainly include Vanillin, Ethyl Vanillin, and Natural Vanillin. The Company's products are used in varied industries, such as human food, animal feed, pet food, agrochemicals, petrochemicals, pharmaceuticals, nutraceuticals, flavors and fragrances, and health care. Its brands include Ezential, Nasure, adorr, Dinamics, Xtendra, and Biosus.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Specialty Chemicals: 130 companies →Camlin Fine Sciences against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)66.7 against a typical 26.3: pricier than most peers (1st = cheapest).107th of 129
- Sales growth+27.5% against a typical +25.9% from a year earlier.52nd of 112
- Share price, 3 months−35.4% against a typical −5.5%.116th of 118
- Size₹ 1,543.7 Cr. market value against a typical ₹ 359.6 Cr. (1st = largest).38th of 126
Credit ratings
Every rating action on file, newest first, including reaffirmations. Open a row for the agency's reasoning. All credit rating updates
Look closer
Rated BBB- by India Ratings- India Ratings lowered its rating on 7 Jan 2026.
| Agency | Current rating | Outlook | As of |
|---|---|---|---|
| India Ratings | IND BBB-; IND A3 | Stable | 7 Jan 2026 |
| Rating | Details | |||||
|---|---|---|---|---|---|---|
| 7 Jan 2026 | ▼ Downgrade | IND BBB- | — | India Ratings | ₹ 469.92 Cr. |
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 11 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 26 May 2026 | Financial Results | To consider and approve the financial results for the period ended March 31, 2026 |
| 13 Feb 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 10 Nov 2025 | Financial Results | To consider and approve the financial results for the period ended September 30, 2025 |
| 29 Sep 2025 | Fund Raising | To consider and approve the proposal for issuance of equity shares of the Company by way of preferential allotment on a private placement basis . |
| 8 Aug 2025 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2025 |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 406 | 386 | 377 | 381 | 417 | 431 | 432 | 408 | 460 | 441 | 425 | 520 |
| Expenses | 381 | 363 | 345 | 352 | 366 | 375 | 370 | 387 | 427 | 420 | 404 | 511 |
| Operating Profit | 25 | 23 | 31 | 29 | 52 | 56 | 62 | 20 | 33 | 21 | 21 | 9 |
| OPM % | 6% | 6% | 8% | 8% | 12% | 13% | 14% | 5% | 7% | 4.7% | 5% | 1.8% |
| Other Income | 2 | 2 | −96 | −15 | −151 | −8 | −22 | 0 | −4 | −24 | 103 | −10 |
| Interest | 20 | 14 | 16 | 23 | 26 | 34 | 15 | 15 | 19 | 17 | 23 | 14 |
| Depreciation | 19 | 21 | 13 | 15 | 17 | 14 | 17 | 16 | 19 | 16 | 21 | 19 |
| Profit before tax | −12 | −10 | −94 | −23 | −142 | 0 | 8 | −11 | −9 | −37 | 80 | −34 |
| Tax % | 72% | 47% | −13% | 48% | −18% | 2,164% | 98% | 0% | 65% | 0% | −8% | −1% |
| Net Profit | −21 | −14 | −82 | −35 | −116 | −7 | 0 | −11 | −15 | −37 | 86 | −34 |
| EPS in Rs | −1.03 | −0.63 | −4.11 | −1.81 | −5.33 | −0.22 | −0.04 | −0.53 | −0.76 | −1.89 | 4.59 | −1.65 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 13%
- 5 Years
- 8%
- 3 Years
- 1%
- TTM
- 9%
- 10 Years
- −1%
- 5 Years
- −6%
- 3 Years
- −14%
- TTM
- −139%
- 10 Years
- 2%
- 5 Years
- −8%
- 3 Years
- −11%
- TTM
- —
- 10 Years
- −1%
- 5 Years
- −2%
- 3 Years
- −7%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Camlin Fine Sciences | ₹ 84.02 | ₹ 1,544 Cr. | 66.7x | 1.6x | 4% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Ashish Subhash Dandekar
- Executive Chairman of the Board, Managing Director
- Pankaj Pandey
- Chief Financial Officer
- Santosh Parab
- Chief Financial Officer
- Rahul Sawale
- Compliance Officer, Vice President - Legal, Company Secretary
- Nirmal Vinod Momaya
- Managing Director, Executive Director
- Arjun Sudhakar Dukane
- Executive Director - Technical
Prices are delayed and for information only. Nothing on this page is investment advice.